An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy.

Trial Profile

An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 13 Apr 2016

At a glance

  • Drugs Delanzomib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 10 May 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 11 Feb 2013 According to European Clinical trials database, this study has been suspended temporarily.
    • 01 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top